Variability of Biologics and its Impact on Biosimilar Development
ERIKA LIETZAN
Zomerportret 1. Huub Schellekens: 'Iedereen moet weer gaan doen waar hij goed in is' | medischcontact
Personalised medicine produced in a “Bionexpresso” - News - Utrecht University
eLearning – Biosimilars: From concern to confidence
Catalogus Professorum - Prof Detail
Immunogenicity and aggregation of therapeutic proteins - American ...
De Affaire Buck - Andere Tijden
Professor Schellekens maakt medicijnen zelf - Zembla - BNNVARA
Oncology Virtual Expo - Springer Healthcare
Cv huub schellekens complet by Ricardo Guerrero - Issuu
Follicular Carcinoma of Thyroid with Bone Metastasis
For complex biosimilars in EU: drop clinical comparability
Huub Schellekens – Studium Generale Universiteit Utrecht
Huub Schellekens - HR Business Partner - Feenstra | LinkedIn
Huub Schellekens – Studium Generale Universiteit Utrecht
A new way to manufacture small batches of biopharmaceuticals on demand | MIT News | Massachusetts Institute of Technology
Huub Schellekens, Professor of pharmaceutical biotechnology at Utrecht University: "We need 20 billion doses for the entire world population"
Huub Schellekens, Professor of pharmaceutical biotechnology at Utrecht University: "We need 20 billion doses for the entire world population"
eLearning module: Improving confidence by explaining key terminology – Biosimilars: From concern to confidence
Huub Schellekens email address & phone number | Feenstra HR Business Partner contact information - RocketReach
Elles de Bruin | Writers Unlimited
D16 Training - Conference Besides having a public session focusing on a specific theme on each of the workshops (M7, M12, M20, M
